Prognostic value of P53, MDM‐2, and MUC‐1 for patients with inflammatory breast carcinoma
- 18 August 2004
- Vol. 101 (5), 913-917
- https://doi.org/10.1002/cncr.20465
Abstract
BACKGROUND Inflammatory breast carcinoma (IBC) is a rare and aggressive malignancy. Therapy for patients with IBC is multidisciplinary, and response to preoperative chemotherapy is considered an important predictor of outcome. Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC. METHODS Immunohistochemical assays for P53, MDM‐2, and MUC‐1 were performed retrospectively to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with IBC. RESULTS After a median follow‐up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC‐1 had a significantly shorter median TTP and median OS compared with other patients. CONCLUSIONS Expression of P53 and MUC‐1 may be predictive of treatment efficacy and outcome for patients with IBC. Furthermore, these two markers may represent novel therapeutic targets in such patients. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 22 references indexed in Scilit:
- Small molecules that reactivate mutant p53European Journal Of Cancer, 2003
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002
- Activation of p53 by roscovitine-mediated suppression of MDM2 expressionOncogene, 2001
- p53 Gene Replacement for Cancer&Interactions with DNA Damaging AgentsActa Oncologica, 2001
- Nuclear exclusion of p53 in a subset of tumors requires MDM2 functionOncogene, 2000
- Inhibitors of Transcription, Proteasome Inhibitors, and DNA-Damaging Drugs Differentially Affect Feedback of p53 DegradationExperimental Cell Research, 1998
- Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer CenterCancer Chemotherapy and Pharmacology, 1997
- The Role of Tumor‐associated Antigens in the Biology and Immunotherapy of Breast CancerAnnals of the New York Academy of Sciences, 1993
- Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Structure and expression of c‐erbB‐2 and EGF receptor genes in inflammatory and non‐inflammatory breast cancer: Prognostic significanceInternational Journal of Cancer, 1989